At Porton Biopharma Limited (PBL) we strive to make high quality medicines for patients and are acutely aware that any interruptions in the supply of Erwinase have serious consequences for patients being treated for Acute Lymphoblastic Leukaemia. As a result, we wish to keep all stakeholders informed of the supply status of Erwinase and commit to do our utmost best to ensure that patients are able to access this life saving product.
Over the past two years, PBL has made significant improvements to its operations and has been consistently manufacturing its life-saving product Erwinase® on schedule and to specification.
PBL is committed to providing this medicine for patients who need it. PBL is confident in the consistent high quality of Erwinase® which is released by Qualified Persons, independently reviewed and continues to make batches available for collection on a regular basis.
PBL announces that it has signed an exclusive, worldwide licensing agreement with Clinigen Group plc (“Clinigen”) for the distribution of Erwinase®/ Erwinaze® (“Erwinase”), the Company’s life-saving treatment for acute lymphoblastic leukaemia, a cancer of the blood predominantly affecting children. The agreement will become effective from January 1st 2021.
Porton Biopharma Limited (“PBL”), the UK biopharmaceutical, development and manufacturing company, notes yesterday’s full year financial results announcement from Jazz Pharmaceuticals PLC, which confirmed that Erwinase®, the Company’s life-saving cancer treatment, recorded sales of more than $177 million in 2019, up 2%.
PBL is proud to have provided support to a team of undergraduate students from Nottingham University who won a Gold Medal at this years international Genetically Engineered Machine (iGEM) competition.
Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract (HHSN272201600045C) with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase. The contract modification is worth US $4.5 million and follows approval by the US Food and Drug Administration (FDA) of the investigational new drug (IND) application
In this case study, Dr David Gervais, Head of Product and Fermentation Development at Porton Biopharma describes how a non-GMP enzyme manufacturing process has been successfully converted from a native to a recombinant one using bioinformatics and next-generation sequencing (NGS).
Demonstrating PBL’s capability to deliver significant improvements in yield, purity and activity for customer’s products.
Porton Biopharma will be attending the Salisbury Jobs fair in the Guildhall on Tuesday 2nd April. Do come along and see us between 9am and 3pm to find out more about what we do and our exciting range of careers.